Understanding EMPA-REG OUTCOME (Q86756711)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Understanding EMPA-REG OUTCOME (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Daniël H van Raalte

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Erik J M van Bommel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Mark M Smits

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Lennart Tonneijck

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

1 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

The Lancet: Diabetes & Endocrinology

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

928-929

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900424-6

7 January 2021

Getting to the heart of the matter in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900424-6

7 January 2021

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900424-6

7 January 2021

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900424-6

7 January 2021

Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900424-6

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900424-6

7 January 2021

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900424-6

7 January 2021

10.1016/S2213-8587(15)00424-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26590679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference